穩健醫療(300888.SZ):控股股東自願承諾延長限售期
格隆匯5月20日丨穩健醫療(300888.SZ)公佈,近日收到控股股東穩健集團有限公司(以下簡稱“穩健集團”)出具的《關於自願延長限售期的承諾》,穩健集團基於對公司未來發展的信心,為進一步加強對公司的支持,本着對上市公司社會公眾股東負責的態度,自願再次承諾延長其所持公司股份的限售期。穩健集團自願再次承諾延長所持穩健醫療股份的限售期,限售期截止日從2024年9月16日延長至2025年9月16日。在限售期內,穩健集團不轉讓或者委託他人管理其持有的該部分穩健醫療股份,也不由穩健醫療回購持有的該部分股份。在限售期內,因穩健醫療實施轉股、送股和配股行為導致穩健集團新獲得的股份,同樣遵守前述限售要求。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.